Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice
Lei Xia,1,* Li Wen,1,2,* Xiangxi Meng,1 Nina Zhou,1 Xiaoyi Guo,1 Teli Liu,1 Xiaoxia Xu,1 Feng Wang,1 Hua Zhu,1 Zhi Yang1 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceutica...
Guardado en:
Autores principales: | Xia L, Wen L, Meng X, Zhou N, Guo X, Liu T, Xu X, Wang F, Zhu H, Yang Z |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/96da9df0855048c999bbc4b3c4fd8012 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
por: Cihan Gündoğan, et al.
Publicado: (2021) -
Comparison of <sup>68</sup>Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer
por: Julien Van Damme, et al.
Publicado: (2021) -
Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
por: Paola Mapelli, et al.
Publicado: (2021) -
PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
por: Maximilian A. Kirchner, et al.
Publicado: (2021) -
68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors
por: Heying Duan, et al.
Publicado: (2022)